vs

Side-by-side financial comparison of Banzai International, Inc. (BNZI) and IMMUCELL CORP (ICCC). Click either name above to swap in a different company.

IMMUCELL CORP is the larger business by last-quarter revenue ($5.5M vs $2.8M, roughly 1.9× Banzai International, Inc.). IMMUCELL CORP runs the higher net margin — -2.5% vs -207.0%, a 204.4% gap on every dollar of revenue. On growth, Banzai International, Inc. posted the faster year-over-year revenue change (163.2% vs -8.4%). Over the past eight quarters, Banzai International, Inc.'s revenue compounded faster (60.2% CAGR vs 3.9%).

Banzai International, Inc. is a SaaS enterprise that develops cloud-based marketing automation platforms. It primarily serves B2B clients across technology, healthcare, and financial services segments in the U.S. market, helping businesses optimize customer engagement, drive demand generation, and improve marketing campaign ROI.

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

BNZI vs ICCC — Head-to-Head

Bigger by revenue
ICCC
ICCC
1.9× larger
ICCC
$5.5M
$2.8M
BNZI
Growing faster (revenue YoY)
BNZI
BNZI
+171.6% gap
BNZI
163.2%
-8.4%
ICCC
Higher net margin
ICCC
ICCC
204.4% more per $
ICCC
-2.5%
-207.0%
BNZI
Faster 2-yr revenue CAGR
BNZI
BNZI
Annualised
BNZI
60.2%
3.9%
ICCC

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
BNZI
BNZI
ICCC
ICCC
Revenue
$2.8M
$5.5M
Net Profit
$-5.9M
$-139.7K
Gross Margin
81.7%
42.9%
Operating Margin
-155.7%
0.4%
Net Margin
-207.0%
-2.5%
Revenue YoY
163.2%
-8.4%
Net Profit YoY
61.8%
80.1%
EPS (diluted)
$-1.64
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BNZI
BNZI
ICCC
ICCC
Q3 25
$2.8M
$5.5M
Q2 25
$3.3M
$6.4M
Q1 25
$3.4M
$8.1M
Q4 24
$7.8M
Q3 24
$1.1M
$6.0M
Q2 24
$1.1M
$5.5M
Q1 24
$1.1M
$7.3M
Q4 23
$1.1M
$5.1M
Net Profit
BNZI
BNZI
ICCC
ICCC
Q3 25
$-5.9M
$-139.7K
Q2 25
$-7.9M
$501.9K
Q1 25
$-3.6M
$1.4M
Q4 24
Q3 24
$-15.4M
$-701.7K
Q2 24
$-4.0M
$-1.5M
Q1 24
$-4.3M
$-437.9K
Q4 23
$-6.4M
Gross Margin
BNZI
BNZI
ICCC
ICCC
Q3 25
81.7%
42.9%
Q2 25
83.0%
43.7%
Q1 25
82.1%
41.6%
Q4 24
36.5%
Q3 24
68.7%
26.3%
Q2 24
69.1%
22.5%
Q1 24
64.7%
31.6%
Q4 23
71.2%
24.7%
Operating Margin
BNZI
BNZI
ICCC
ICCC
Q3 25
-155.7%
0.4%
Q2 25
-144.2%
8.8%
Q1 25
-145.2%
13.9%
Q4 24
8.0%
Q3 24
-256.5%
-9.6%
Q2 24
-315.7%
-25.3%
Q1 24
-315.2%
-4.1%
Q4 23
-295.5%
-19.7%
Net Margin
BNZI
BNZI
ICCC
ICCC
Q3 25
-207.0%
-2.5%
Q2 25
-243.1%
7.8%
Q1 25
-107.8%
17.9%
Q4 24
Q3 24
-1426.4%
-11.7%
Q2 24
-370.3%
-28.0%
Q1 24
-397.4%
-6.0%
Q4 23
-588.7%
EPS (diluted)
BNZI
BNZI
ICCC
ICCC
Q3 25
$-1.64
$-0.02
Q2 25
$-4.08
$0.06
Q1 25
$-0.15
$0.16
Q4 24
$0.09
Q3 24
$-48.73
$-0.09
Q2 24
$-14.09
$-0.20
Q1 24
$-1.64
$-0.06
Q4 23
$-4.54
$-0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BNZI
BNZI
ICCC
ICCC
Cash + ST InvestmentsLiquidity on hand
$851.4K
$3.9M
Total DebtLower is stronger
$9.5M
Stockholders' EquityBook value
$5.4M
$29.8M
Total Assets
$33.0M
$45.7M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BNZI
BNZI
ICCC
ICCC
Q3 25
$851.4K
$3.9M
Q2 25
$2.3M
Q1 25
$780.8K
Q4 24
$3.8M
Q3 24
$4.3M
Q2 24
$471.7K
$1.3M
Q1 24
$1.0M
$960.3K
Q4 23
$2.1M
$978.7K
Total Debt
BNZI
BNZI
ICCC
ICCC
Q3 25
$9.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Q4 23
$10.5M
Stockholders' Equity
BNZI
BNZI
ICCC
ICCC
Q3 25
$5.4M
$29.8M
Q2 25
$3.0M
$29.9M
Q1 25
$2.9M
$29.0M
Q4 24
$27.5M
Q3 24
$-22.8M
$26.4M
Q2 24
$-31.8M
$23.5M
Q1 24
$-30.8M
$24.6M
Q4 23
$25.0M
Total Assets
BNZI
BNZI
ICCC
ICCC
Q3 25
$33.0M
$45.7M
Q2 25
$34.7M
$46.7M
Q1 25
$33.7M
$45.6M
Q4 24
$45.1M
Q3 24
$7.3M
$44.4M
Q2 24
$3.8M
$41.9M
Q1 24
$4.4M
$43.1M
Q4 23
$5.3M
$43.8M
Debt / Equity
BNZI
BNZI
ICCC
ICCC
Q3 25
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×
Q4 23
0.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BNZI
BNZI
ICCC
ICCC
Operating Cash FlowLast quarter
$-4.4M
$-1.2M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-32.3%
Capex IntensityCapex / Revenue
10.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BNZI
BNZI
ICCC
ICCC
Q3 25
$-4.4M
$-1.2M
Q2 25
$-4.0M
$1.6M
Q1 25
$-5.0M
$1.6M
Q4 24
$-3.1K
Q3 24
$-1.6M
$-639.3K
Q2 24
$-1.7M
$581.8K
Q1 24
$-2.1M
$418.5K
Q4 23
$4.3M
$-723.1K
Free Cash Flow
BNZI
BNZI
ICCC
ICCC
Q3 25
$-1.8M
Q2 25
$1.4M
Q1 25
$1.2M
Q4 24
$-199.3K
Q3 24
$-727.7K
Q2 24
$471.0K
Q1 24
$348.1K
Q4 23
$-804.4K
FCF Margin
BNZI
BNZI
ICCC
ICCC
Q3 25
-32.3%
Q2 25
22.4%
Q1 25
15.4%
Q4 24
-2.6%
Q3 24
-12.1%
Q2 24
8.6%
Q1 24
4.8%
Q4 23
-15.8%
Capex Intensity
BNZI
BNZI
ICCC
ICCC
Q3 25
10.8%
Q2 25
2.4%
Q1 25
4.1%
Q4 24
2.5%
Q3 24
1.5%
Q2 24
2.0%
Q1 24
1.0%
Q4 23
1.6%
Cash Conversion
BNZI
BNZI
ICCC
ICCC
Q3 25
Q2 25
3.19×
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BNZI
BNZI

Other$1.7M60%
Banzai Operating$1.1M40%

ICCC
ICCC

Segment breakdown not available.

Related Comparisons